Effects of doripenem injection: A Synthesis of Findings from 12 Studies

  1. Home
  2. Effects of doripenem injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of doripenem injection: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of doripenem injection: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Doripenem has been shown to be effective against carbapenem-resistant Acinetobacter baumannii (CRAB) in experimental sepsis. 5 . Combination therapies with doripenem were more effective than monotherapy in a mouse sepsis model. 5 . The combination of doripenem with tigecycline or amikacin had a more rapid bactericidal effect than doripenem with sulbactam or colistin. 5 . In a phase III study, doripenem was found to be non-inferior to meropenem in treating complicated intra-abdominal infections (cIAIs). 10 . Doripenem has a favorable safety profile and showed no convulsive liability in comparison with other beta-lactam antibiotics. 11 .

Benefits and Risks

Benefit Summary

Doripenem is a valuable treatment option for infections caused by multi-drug resistant bacteria, particularly carbapenem-resistant Acinetobacter baumannii. 5 . Doripenem has been shown to be effective for treating complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (UTIs). 10 , 6 . Doripenem has a lower risk of causing seizures compared to other beta-lactam antibiotics. 11 .

Risk Summary

Doripenem, like other antibiotics, can cause side effects. The most common side effects are diarrhea, vomiting, nausea, and rash. 9 , 6 . Serious side effects include seizures, anaphylaxis, and liver dysfunction. 9 , 6 .

Comparison Between Studies

Commonalities

These studies consistently show that doripenem is a promising treatment option for infections caused by multi-drug resistant bacteria. 5 , 10 , 6 . They also suggest that doripenem has a lower risk of causing seizures compared to other beta-lactam antibiotics. 11 .

Differences

The studies differ in their specific focus, methodologies, and sample sizes. For instance, 5 investigates the efficacy of doripenem in a mouse model of sepsis, while 10 , 6 , and 11 conducted human clinical trials. This makes direct comparison of the results challenging. Nonetheless, these studies collectively suggest that doripenem is a potentially effective treatment for a range of infections.

Consistency and Contradictions in Results

While these studies indicate the effectiveness of doripenem, some inconsistencies are observed. For example, 5 suggests that combining doripenem with tigecycline or amikacin leads to a more rapid reduction in bacterial load compared to combinations with sulbactam or colistin. However, 10 found doripenem to be non-inferior to meropenem in treating complicated intra-abdominal infections (cIAIs). These inconsistencies could be attributed to factors like differences in infection types, methodologies, sample sizes, and the specific bacterial strains investigated.

Implications for Everyday Life

Doripenem is a potential treatment option for infections caused by multi-drug resistant bacteria. However, like all antibiotics, doripenem can cause side effects. It is crucial to follow your doctor's instructions carefully when taking doripenem and avoid self-treating or adjusting the dosage without their guidance.

Limitations of Current Research

The research on doripenem has some limitations. The study in 5 was based on animal experiments, and its applicability to humans is uncertain. The sample sizes in 10 and 6 were relatively small, potentially limiting the generalizability of the findings. Additionally, the long-term safety of doripenem has not yet been fully assessed.

Future Research Directions

To strengthen the evidence base for doripenem, larger-scale human clinical trials are required. Further research is needed to assess the long-term safety and efficacy of doripenem. More detailed studies are also necessary to evaluate the effectiveness of combination therapies involving doripenem and other antibiotics.

Conclusion

Doripenem shows promise as a treatment for infections caused by multi-drug resistant bacteria. However, it's crucial to remember that doripenem can cause side effects, and careful adherence to medical advice is vital. Future research has the potential to further clarify the safety and efficacy of doripenem in various clinical settings.

Literature analysis of 12 papers
Positive Content
10
Neutral Content
0
Negative Content
2
Article Type
3
0
0
1
12
1.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Author: KhaliliehSauzanne G, YeeKa Lai, FanLi, LiuRachael, HeberWalter, DunzoElise, TriantafyllouIlias, HussainiAzra, IwamotoMarian

HIV treatment
QTc prolongation

Doravirine, a novel HIV-1 non-nucleoside reverse transcriptase inhibitor, had no significant effects on the heart-rate corrected QT (QTc) interval in healthy adults when administered at a supratherapeutic dose.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Effects of sewer biofilms on the degradability of carbapenems in wastewater using laboratory scale bioreactors.

Author: SharmaElipsha, SivakumarMuttucumaru, KelsoCeline, ZhangShuxin, ShiJiahua, GaoJianfa, GaoShuhong, ZhouXu, JiangGuangming

Wastewater epidemiology
Carbapenem degradation

This study investigated the degradation of carbapenems, a class of antibiotics, in sewer environments. The findings suggest that sewer biofilms play a significant role in carbapenem degradation, potentially impacting their environmental fate.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Pharmacokinetics and brain penetration of carbapenems in mice.

Author: MatsumotoKazuaki, KuriharaYuji, KurodaYuko, HoriSeiji, KizuJunko

CNS toxicity
Seizures

This study examined the pharmacokinetics and brain penetration of four carbapenems in mice. Imipenem was found to penetrate brain tissue to the greatest extent, suggesting a potential risk of CNS toxicity with this drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.

Author: RedmanR, DamiaoR, KoteyP, KanigaK, DaviesT, NaberK G

Pyelonephritis treatment
Urinary tract infection treatment

Doripenem, a carbapenem antibiotic, was compared to levofloxacin for treating complicated urinary tract infections and pyelonephritis in two phase 3 studies. Microbiological eradication rates were similar between the two drugs. However, doripenem showed significantly better outcomes in patients infected with levofloxacin-resistant Escherichia coli. Doripenem was found to be safe and well tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Doripenem: a new carbapenem antibiotic.

Author: ChahineElias B, FerrillMary J, PoulakosMara N

Effective for infections
Allergic reactions
Gastrointestinal issues

Doripenem is a carbapenem antibiotic with a broad spectrum of activity comparable to imipenem and meropenem. It has a favorable safety profile and is effective in treating complicated intraabdominal infections, complicated urinary tract infections, ventilator-associated pneumonia, and hospital-acquired pneumonia.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Safety of intravenous infusion of doripenem.

Author: RedmanRebecca, FileThomas M

Nosocomial infection treatment
Seizures

Doripenem, a new carbapenem antibiotic, has a favorable safety profile comparable to other carbapenems and demonstrates a limited propensity to induce seizures.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Author: LucastiChristopher, JasovichAbel, UmehObiamiwe, JiangJoel, KanigaKoné, FriedlandIan

Effective cIAI treatment
Noninferior to meropenem
Safe
Adverse events
Death

Doripenem (500 mg q8h) was effective in the treatment of complicated intra-abdominal infections (cIAIs), was therapeutically noninferior to meropenem (1 g q8h), with a safety profile not significantly different from that of meropenem.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.